Mineralys Therapeutics (MLYS) announced detailed results from the Phase 2 Advance-HTN trial, one of two pivotal trials evaluating lorundrostat ...

Among patients with uncontrolled hypertension, the investigational drug lorundrostat brought a significant reduction in blood pressure at 12 weeks compared with placebo, according to a study presented ...

The investigational aldosterone synthase inhibitor lorundrostat effectively lowered 24-hour BP for adults with well-treated, uncontrolled and “true” treatment-resistant hypertension, according to data ...